Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $18 from $21 and keeps an Equal Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies price target lowered to $19 from $21 at JPMorgan
- Adaptive Biotechnologies price target raised to $21 from $19 at TD Cowen
- Adaptive Biotechnologies Wins Buy Rating on Surging MRD Revenue, Raised Guidance, and Clear Path to Profitability
- Adaptive Biotechnologies Leans on MRD in Earnings Call